Table 5.

Impact of SIR markers in patients with LAPC and mPDAC

	LAPC				mPDAC
	Months (95% CI)	p	HR (95% CI)	p	Months (95% CI)	p	HR (95% CI)	p
All	26.4 (22.3–30.6)	< 0.001	2.693 (1.816–3.992)	< 0.001	9.4 (7.5–11.2)
LMR   > 2.8   < 2.8	19.7 (4.8–34.7) 21.1 (11.9–30.3)	0.291	1.695 (0.626–4.589)	0.299	9.7 (8.3–11.3) 5.4 (2.9–7.8)	0.016	1.816 (1.111–2.970)	0.017
NLR   < 5   > 5	21.1 (18.5–23.7) 7.3 (n.a.)	0.333	2.093 (0.449–9.746)	0.347	8.7 (7.1–10.3) 4.7 (3.7–5.8)	0.018	1.724 (1.090–2.725)	0.020
CRP   < 5 mg/dl   > 5 mg/dl	21.1 (18.2–23.9) n.a	n.a	n.a	n.a	9.5 (8.2–10.9) 3.9 (2.8–5.0)	< 0.001	2.174 (1.401–3.376)	0.001
mGPS  0   > 0	21.1 (12.8–29.4) 15.0 (0.0–33.3)	0.112	2.376 (0.788–7.167)	0.124	10.8 (8.8–12.8) 5.1 (3.5–6.7)	0.007	1.849 (1.178–2.901)	0.008

LMR lymphocyte-monocyte ratio, NLR neutrophil–lymphocyte ratio, CRP C-reactive protein, mGPS modified Glasgow Prognostic Score, LAPC locally advanced pancreatic cancer, mPDAC metastatic pancreatic ductal adenocarcinoma